CadheRx is developing therapeutic antibodies targeting soluble E-cadherin (sEcad) for the treatment of solid tumors that are resistant to other treatments, particularly Cetuximab and Herceptin resistant epithelial cancers. sEcad levels are increased in many epithelial cancers and result in increased tumor cell proliferation, migration, invasion and angiogenesis. In vitro and in vivo studies have shown that antibodies targeting sEcad inhibit cell proliferation and promote cell death through apoptotic pathways in EGFR+/KRAS+ or BRAF+ Cetuximab resistant cell lines and tumors, as well as Her2+/Herceptin resistant cell lines and tumors. CadheRx was founded on intellectual property in-licensed from the laboratory of Sabine Brouxhon, M.D., Clinical Associate Professor, Department of Emergency Medicine in the School of Medicine at Stony Brook University.

Key Contact